HIV/AIDS Therapy
Enrollment completed in trial of AIDS vaccine
Published in AIDS Weekly, January 23rd, 2006
The study will compare two doses of the MVA nef vaccine (5x10 E8 and 10E8) with Imvamune (10E8) in subjects with CD4 counts down to 250 cells/microliter. This group of patients has a more advanced state of the HIV disease than those patients studied in the company's earlier phase I/II study.
To-date, no serious or unexpected reactions were seen in these patients after vaccination with the MVA nef vaccine or Imvamune. In addition, initial data confirms that the vaccine is strongly immunogenic and thereby reinforces the promising results...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2006-01-23)
More Articles from AIDS Weekly
- Genetics & Genomics
South African GB virus C genotypes inhibit HIV replication - HIV/AIDS Drug Adherence
Obtaining refills via pill organizers dispensed by pharmacist improves HAART adherence - HIV/AIDS Drug Interaction
Didenosine EC AUC is increased when dosed along with tenofovir DF - HIV/AIDS Pathogenesis
HIV-1 VPR protects against lethal superantigen challenge while maintaining T cell levels - HIV/AIDS Pathogenesis
Tat-specific CD8 cells suppress SIV replication more effectively than Gag-specific cells - Adolescent Health
Study supports goal of abstinence but is critical of abstinence-only programs - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
